Product Description
Takeda is developing Danavorexton as a treatment for sleep apnea. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT05180890)
Mechanisms of Action: OX2R Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Takeda
Company Location: Asia Pacific
Company Founding Year: 1781
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Sleep Apnea, Obstructive
Phase 1: Sleep Apnea, Obstructive|Disorders of Excessive Somnolence|Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05180890 |
TAK-925-1020 | P1 |
Completed |
Sleep Apnea, Obstructive |
2022-11-23 |
88% |
2024-06-06 |
Primary Endpoints|Treatments |
NCT05025397 |
TAK-925-1019 | P1 |
Completed |
Healthy Volunteers |
2022-03-08 |
50% |
2024-06-06 |
Primary Endpoints|Treatments |
JapicCTI-195087 |
JapicCTI-195087 | P1 |
Unknown |
Unknown |
2020-11-25 |
12% |
||
NCT04091438 |
TAK-925-2002 | P1 |
Completed |
Disorders of Excessive Somnolence |
2020-11-19 |
12% |
2023-09-27 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT04091425 |
TAK-925-2001 | P1 |
Completed |
Sleep Apnea, Obstructive |
2020-04-02 |
88% |
2020-04-21 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
JapicCTI-184207 |
JapicCTI-184207 | P1 |
Unknown |
Narcolepsy |
2019-10-24 |
50% |
||
NCT03748979 |
TAK-925-1003 | P1 |
Completed |
Narcolepsy |
2019-10-24 |
50% |
2024-06-06 |
Primary Endpoints |
NCT03522506 |
TAK-925-1002 | P1 |
Completed |
Healthy Volunteers |
2018-11-07 |
19% |
2024-06-06 |
Primary Endpoints|Treatments |
NCT03332784 |
TAK-925-1001 | P1 |
Completed |
Narcolepsy |
2018-09-04 |
26% |
2024-06-06 |
Primary Endpoints |
JapicCTI-173756 |
JapicCTI-173756 | P1 |
Unknown |
Narcolepsy |
2018-09-04 |
26% |
||
NCT05814016 |
TAK-925-1501 | P2 |
Terminated |
Sleep Apnea, Obstructive |
2024-09-25 |
12% |
2024-11-01 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |